Evidence map›Paper›PMID 40746217›Full record

ArticleTurkish journal of pharmaceutical sciences2025

Effect of PGV-1 on Apoptosis

Nadzifa Nugraheni, Beni Lestari, Edy Meiyanto, Rohmad Yudi Utomo

Abstract read
In one paragraph

Article in Turkish journal of pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nadzifa NugraheniUniversitas Gadjah Mada, Graduate School of Biotechnology, Yogyakarta, Indonesia.ORCID 0000-0003-1918-0155
Beni LestariUniversitas Gadjah Mada, Faculty of Medicine, Department of Pharmacology and Therapy, Division of Public Health and Nursing, Yogyakarta, Indonesia.ORCID 0000-0002-5658-0572
Edy MeiyantoUniversitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Laboratory of Macromolecular Engineering, Yogyakarta, Indonesia.ORCID 0000-0002-0886-6322
Rohmad Yudi UtomoUniversitas Gadjah Mada, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Laboratory of Medicinal Chemistry, Yogyakarta, Indonesia.ORCID 0000-0003-4803-9417

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Senescent cells release a senescence-associated secretory phenotype, promoting polyploid giant cancer cells (PGCCs) to emerge, fostering tumor heterogeneity and resistance. Pentagamavunone-1 (PGV-1) emerges as a promising agent inducing senescence and prometaphase arrest, resulting in permanent cytotoxicity. This study was aimed to investigate the effect of PGV-1 in dysregulating mitosis through the modulation of PGCCs and senescence in low MYCN-expressing hepatocellular carcinoma (HCC) cells JHH4. Materials and Methods: To assess the physiological effects of PGV-1, several Results: The cytotoxic assay revealed that PGV-1 inhibited the proliferation of JHH4 liver cancer cells permanently. Inhibition of cell proliferation by PGV-1 was associated with the modulation of G2/M phase, particularly mitotic arrest and formation of PGCCs. The SA-β-Gal verified that PGV-1 induced senescence in cells ( Conclusion: PGV-1 induced strong cytotoxicity in HCC cells by disrupting mitosis leading to PGCC formation, senescence, and subsequent apoptotic cell death.

Indexed as

apoptosishepatocellular carcinomaPGV-1polypoid giant cancer cellssenescence

Identifiers

PMID40746217
PMCPMC12316068

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.